Kintor Pharma Receives NMPA’s IND Clearance for KX-826 to Treat Male Androgenetic Alopecia (AGA)
Shots:
- The NMPA has cleared an IND application for a P-III study to evaluate the efficacy and safety of KX-826 in patients with male AGA across 20+ sites in China. The first patient is expected to enroll in early Jan 2022
- The 1EPs of the trial is the change from baseline in non-vellus TAHC at the end of 24wks.
- On Sept 08, 2021, the P-II trial meet its 1EPs & demonstrated a good efficacy and safety profile of KX-826. On Jul 11, 2021, the therapy has received the US FDA’s approval for AGA
Ref: Kintor Pharma | Image: Kintor Pharma
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com